Integrity Applications Signs Distribution Agreement For GlucoTrack® Model DF-F Glucose Monitoring Device

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ASHKELON, Israel--(BUSINESS WIRE)--Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack® model DF-F non-invasive blood glucose measurement device, has entered into a distribution agreement appointing Ultramedix Australasia Pty Ltd., with their depth of specialist clinical expertise and expertise in engineering, sales and marketing in the high-tech medical industry, as the exclusive distributor of the GlucoTrack device in Australia and New Zealand. The appointment is subject to, and will take effect 14 days after, the approval of the listing of the GlucoTrack model DF-F device on the Australian Register of Therapeutic Goods (ARTG) register. According to the International Diabetes Federation, nearly 2 million diabetes patients live in Australia and New Zealand combined.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC